Annals of the Rheumatic Diseases: 80 (10)

Editorials

SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future (13 September, 2021) Free
Kevin L Winthrop, Richard J Whitley, Daniel Aletaha
Call for emergency action to limit global temperature increases, restore biodiversity and protect health (5 September, 2021)
Lukoye Atwoli, Abdullah H Baqui, Thomas Benfield, Raffaella Bosurgi, Fiona Godlee, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Carlos Augusto Monteiro, Ian Norman, Kirsten Patrick, Nigel Praities, Marcel GM Olde Rikkert, Eric J Rubin, Peush Sahni, Richard Smith, Nicholas J Talley, Sue Turale, Damián Vázquez

Reviews

Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases (7 September, 2021) Free
Marcia A Friedman, Jeffrey R Curtis, Kevin L Winthrop
Message from the new EULAR President and Steering Group (26 August, 2021) Free
Annamaria Iagnocco, Daniel Aletaha, Xenofon Baraliakos, Iain B McInnes
Preclinical models of arthritis for studying immunotherapy and immune tolerance (11 August, 2021)
Gavin R Meehan, Ranjeny Thomas, Shaima Al Khabouri, Pascale Wehr, Catharien MU Hilkens, David C Wraith, Daniela Sieghart, Michael Bonelli, György Nagy, Paul Garside, David F Tough, Huw D Lewis, James M Brewer

Recommendations

2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis (7 May, 2021)
Elena Nikiphorou, Eduardo José Ferreira Santos, Andrea Marques, Peter Böhm, Johannes WJ Bijlsma, Claire Immediato Daien, Bente Appel Esbensen, Ricardo J O Ferreira, George E Fragoulis, Pat Holmes, Hayley McBain, George S Metsios, Rikke Helene Moe, Tanja A Stamm, Annette de Thurah, Condruta Zabalan, Loreto Carmona, Ailsa Bosworth
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis (6 August, 2021)
Kulveer Mankia, Heidi J Siddle, Andreas Kerschbaumer, Deshire Alpizar Rodriguez, Anca Irinel Catrina, Juan D Cañete, Andrew P Cope, Claire Immediato Daien, Kevin D Deane, Hani El Gabalawy, Axel Finckh, V Michael Holers, Marios Koloumas, Francesca Ometto, Karim Raza, Condruta Zabalan, Annette van der Helm-van Mil, Dirkjan van Schaardenburg, Daniel Aletaha, Paul Emery
EULAR recommendations for intra-articular therapies (25 May, 2021)
Jacqueline Uson, Sebastián Cruz Rodriguez-García, Raul Castellanos-Moreira, Terence W O'Neill, Michael Doherty, Mikael Boesen, Hemant Pandit, Ingrid Möller Parera, Valentina Vardanyan, Lene Terslev, Willm Uwe Kampen, Maria-Antonietta D'Agostino, Francis Berenbaum, Elena Nikiphorou, Irene A Pitsillidou, Jenny de la Torre-Aboki, Loreto Carmona, Esperanza Naredo

Epidemiology

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort (24 March, 2021)
Ulf M Geisen, Dennis K Berner, Florian Tran, Melike Sümbül, Lena Vullriede, Maria Ciripoi, Hayley M Reid, Annika Schaffarzyk, Ann C Longardt, Jeanette Franzenburg, Paula Hoff, Jan H Schirmer, Rainald Zeuner, Anette Friedrichs, Andrea Steinbach, Christine Knies, Robert DH Markewitz, Peter J Morrison, Sascha Gerdes, Stefan Schreiber, Bimba F Hoyer
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases (6 May, 2021)
David Simon, Koray Tascilar, Filippo Fagni, Gerhard Krönke, Arnd Kleyer, Christine Meder, Raja Atreya, Moritz Leppkes, Andreas E Kremer, Andreas Ramming, Milena L Pachowsky, Florian Schuch, Monika Ronneberger, Stefan Kleinert, Axel J Hueber, Karin Manger, Bernhard Manger, Carola Berking, Michael Sticherling, Markus F Neurath, Georg Schett
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2 (18 June, 2021)
Yolanda Braun-Moscovici, Marielle Kaplan, Maya Braun, Doron Markovits, Samy Giryes, Kohava Toledano, Yonit Tavor, Katya Dolnikov, Alexandra Balbir-Gurman
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression (6 August, 2021)
Maria Prendecki, Candice Clarke, Helena Edwards, Stacey McIntyre, Paige Mortimer, Sarah Gleeson, Paul Martin, Tina Thomson, Paul Randell, Anand Shah, Aran Singanayagam, Liz Lightstone, Alison Cox, Peter Kelleher, Michelle Willicombe, Stephen P McAdoo
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study (14 June, 2021)
Victoria Furer, Tali Eviatar, Devy Zisman, Hagit Peleg, Daphna Paran, David Levartovsky, Michael Zisapel, Ofir Elalouf, Ilana Kaufman, Roni Meidan, Adi Broyde, Ari Polachek, Jonathan Wollman, Ira Litinsky, Katya Meridor, Hila Nochomovitz, Adi Silberman, Dana Rosenberg, Joy Feld, Amir Haddad, Tal Gazzit, Muna Elias, Nizar Higazi, Fadi Kharouf, Gabi Shefer, Orly Sharon, Sara Pel, Sharon Nevo, Ori Elkayam
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease (25 May, 2021)
Rebecca H Haberman, Ramin Herati, David Simon, Marie Samanovic, Rebecca B Blank, Michael Tuen, Sergei B Koralov, Raja Atreya, Koray Tascilar, Joseph R Allen, Rochelle Castillo, Amber R Cornelius, Paula Rackoff, Gary Solomon, Samrachana Adhikari, Natalie Azar, Pamela Rosenthal, Peter Izmirly, Jonathan Samuels, Brian Golden, Soumya M Reddy, Markus F Neurath, Steven B Abramson, Georg Schett, Mark J Mulligan, Jose U Scher
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity (20 July, 2021)
Daniel Mrak, Selma Tobudic, Maximilian Koblischke, Marianne Graninger, Helga Radner, Daniela Sieghart, Philipp Hofer, Thomas Perkmann, Helmuth Haslacher, Renate Thalhammer, Stefan Winkler, Stephan Blüml, Karin Stiasny, Judith H Aberle, Josef S Smolen, Leonhard X Heinz, Daniel Aletaha, Michael Bonelli

Letters

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases (24 May, 2021)
Jake A Ruddy, Caoilfhionn Marie Connolly, Brian J Boyarsky, William A Werbel, Lisa Christopher-Stine, Jacqueline Garonzik-Wang, Dorry L Segev, Julie J Paik
Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City (22 June, 2021)
Medha Barbhaiya, Jonah M. Levine, Vivian P. Bykerk, Deanna Jannat-Khah, Lisa A. Mandl
SARS-COV-2 vaccination after stem cell transplantation for scleroderma (28 May, 2021)
Doron Rimar, Gleb slobodin, Alona Paz, Israel Henig, Tsila Zuckerman
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response (6 May, 2021)
Michael Markus Bonelli, Daniel Mrak, Thomas Perkmann, Helmuth Haslacher, Daniel Aletaha
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases (11 May, 2021)
Robert Spiera, Sarah Jinich, Deanna Jannat-Khah
Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report (16 July, 2021)
Basil Golding, Youri Lee, Hana Golding, Surender Khurana
Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response (24 June, 2021)
Fredrik N Albach, Gerd R Burmester, Robert Biesen
Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation (6 May, 2021)
Marlou T H F Janssen, Sofia Ramiro, Robert B M Landewé, César Magro-Checa, Rémy L M Mostard
Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs (13 April, 2021)
Lotte van Ouwerkerk, Andrea E van der Meulen-de Jong, Maarten K Ninaber, Y K Onno Teng, Tom WJ Huizinga, Cornelia F Allaart
Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases (24 August, 2021)
Teresa Po-Yu Chiang, Caoilfhionn M Connolly, Jake A Ruddy, Brian J Boyarsky, Jennifer L Alejo, William A Werbel, Allan Massie, Lisa Christopher-Stine, Jacqueline Garonzik-Wang, Dorry L Segev, Julie J Paik

Electronic pages

Correspondence on ‘EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs’ (27 April, 2021)
Serena Bugatti, Silvia Balduzzi, Ludovico De Stefano, Antonio Manzo, Blerina Xoxi, Laura Bogliolo, Sara Monti, Paolo Delvino, Carlomaurizio Montecucco
Response to: ‘Correspondence on ‘EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs’’ by Bugatti et al
(27 April, 2021)
Johannes W J Bijlsma
Correspondence on ‘Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’ (28 May, 2021) Free
Chiara Salviani, Francesco Scolari, Federico Alberici
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’ (24 May, 2021)
Giuseppe A Ramirez, Emanuel Della-Torre, Luca Moroni, Mona-Rita Yacoub, Lorenzo Dagna
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’ (10 June, 2021)
Jesse Veenstra, Jie Wang, Kathleen McKinnon-Maksimowicz, Tingting Liu, Bobby Zuniga, Iltefat Hamzavi, Li Zhou, Qing-Sheng Mi
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’ (29 June, 2021)
Larissa Valor-Méndez, Koray Tascilar, David Simon, Joerg Distler, Arnd Kleyer, Georg Schett, Juergen Rech
Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’ (16 July, 2021)
Timm H Westhoff, Felix S Seibert, Moritz Anft, Arturo Blazquez-Navarro, Sarah Skrzypczyk, Adrian Doevelaar, Bodo Hölzer, Krystallenia Paniskaki, Sebastian Dolff, Benjamin Wilde, Oliver Witzke, Juergen Braun, Ulrik Stervbo, Nina Babel
Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff et al
(16 July, 2021)
Michael Bonelli, Daniel Aletaha
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
(2 August, 2021)
Caoilfhionn Marie Connolly, Darya Koenig, Srekar N Ravi, Antoine Azar, Sam Kant, Monika Dalal, Jessica Duchen, Philip Seo, Brendan Antiochos, Julie J Paik, Duvuru Geetha
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
(2 August, 2021)
Sarah H Chung, Mark Wener, Alison M Bays, Habib Rahbar, Chihiro Morishima, Andrew B Bryan, Susan L Fink, Seth Cohen, Nandita S Mani, Anu Chaudhary, Gregory C Gardner
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response”by Bonelli et al
(2 August, 2021)
Maurizio Benucci, Arianna Damiani, Maria Infantino, Mariangela Manfredi, Valentina Grossi, Barbara Lari, Francesca Li Gobbi, Piercarlo Sarzi Puttini
Response to: Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
(2 August, 2021)
Michael Bonelli, Daniel Aletaha
Correspondence on ‘SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists’ (7 May, 2021)
Gianluca Smerilli, Edoardo Cipolletta, Erica Moscioni, Francesca Francioso, Anna Maria Risa, Vincenzo Maccarrone, Davide Zompa, Andrea Di Matteo, Marco Di Carlo, Rossella De Angelis, Fausto Salaffi, Emilio Filippucci, Walter Grassi
Response to: ‘Correspondence on ‘SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists’’ by Smerilli et al
(7 May, 2021)
Roberta Priori, Greta Pellegrino, Serena Colafrancesco, Cristiano Alessandri, Fulvia Ceccarelli, Manuela Di Franco, Valeria Riccieri, Rossana Scrivo, Antonio Sili Scavalli, Francesca Romana Spinelli, Fabrizio Conti
Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ (28 January, 2021)
Shamma Al Nokhatha, Neil MacEoin, Richard Conway
Response to: ‘Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ by Nokhatha et al
(28 January, 2021)
Christian Dejaco, Johannes WJ Bijlsma, Frank Buttgereit

Main menu

Table of contents

October 2021 - Volume 80 - 10

Editorials

Reviews

Recommendations

Epidemiology

Letters

Electronic pages

Issue Information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

October 2021 - Volume 80 - 10

Editorials

Reviews

Recommendations

Epidemiology

Letters

Electronic pages

Issue Information